Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We have experience in trials in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis. We run research from early phase through to large scale phase 3 multi-centre trials.

We have experience in trials in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis. The group runs a translational research programme which has as its focus a dual aim. Firstly, to test novel therapeutic approaches in early phase development in musculoskeletal disease in areas of unmet clinical need and to design experimental medicine studies that will permit investigation of the mechanism of action and provide understanding of the biological role of the drug target in vivo. Secondly, in parallel, to test the sensitivity of novel measures of outcome linked to the pathobiology of the disease that might provide an early, reliable and sensitive indication that will inform a rational decision as to whether to progress a potential pharmacotherapeutic to later phase clinical studies for which the primary endpoint is designed to meet the regulatory criteria necessary to gain a drug license for clinical use. 

Our group has already conducted the first ever studies to test potential therapeutic agents for rheumatoid arthritis in a double-blind, parallel group, placebo and active comparator controlled study in which the primary endpoints were two dimensional ultrasonographic measures of inflammation. Professor Taylor is the Chief Investigator for studies designed to investigate the performance of novel imaging endpoints in the context of multi-centre trials of new highly targeted “small molecule” oral therapeutics.